Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Nov 2019 Status changed from active, no longer recruiting to completed.
- 23 Jan 2019 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
- 23 Jan 2019 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2019.